Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight inflows into Kuaishou, Wuxi Biologics, and Hong Kong Exchange.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight inflows into Kuaishou, Wuxi Biologics, and Hong Kong Exchange.


Hong Kong Connect Flows: Kuaishou, Wuxi Biologics, HKEx

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The key task of medical system reform in 2022 is to promote service price reform. There would be overall medical service price increase, but not all hospitals would be benefit.</li>
<li>The primary market financing of medical device CXO industry has become very hot in the past two years, but it could be challenging to form a complete industrial chain.</li>
<li>The lifting of lockdown in Shanghai/Beijing significantly reduces the pressure on supply chain and hospital operations. However, there would still be lockdown in places where positive cases are found. </li>
</ul>


The key task of medical system reform in 2022 is to promote service price reform. There would be overall medical service price increase, but not all hospitals would be benefit.
The primary market financing of medical device CXO industry has become very hot in the past two years, but it could be challenging to form a complete industrial chain.
The lifting of lockdown in Shanghai/Beijing significantly reduces the pressure on supply chain and hospital operations. However, there would still be lockdown in places where positive cases are found. 


China Healthcare Weekly (Jun.10) - Medical Service Price Reform, Medical Device CXO, Lockdown Lifted

Asia biased macro & technical analysis, Untying The Gordian Knot

Untying The Gordian Knot

Asia biased macro & technical analysis

A differentiated process with a primary focus on Asia. Technical Analysis as core and Macro drivers that could bring the view to fruition & changes that could make the idea fall apart. The objective is to be the best in class, hence corner shop.

Technical Analysis

<ul><li>I got Alibaba spectacularly wrong. The government allowed the release of new games and eased some restrictions on the tech sector.</li><li>The mood turned positive, helped by record inflows in Index funds and short covering. It helped Alibaba to rally spectacularly.</li><li>As I am looking for a retest of technology stocks, I will go for stop out until I get more clarity on long ideas.</li></ul>

I got Alibaba spectacularly wrong. The government allowed the release of new games and eased some restrictions on the tech sector.The mood turned positive, helped by record inflows in Index funds and short covering. It helped Alibaba to rally spectacularly.As I am looking for a retest of technology stocks, I will go for stop out until I get more clarity on long ideas.

Hang Seng Index Constituents 8th June 2022

<ul>
<li>We analyze the monthly Hong Kong Connect flows with our data engine.</li>
<li>We tabulate the top stocks by inflows, outlfows, and holding by mainland investors.</li>
<li>Inflows last month amounted to USD 5.7bn which marks sixth months of inflows. Top three stocks southbound investors bought were Meituan, CNOOC, and Tencent.</li>
</ul>


We analyze the monthly Hong Kong Connect flows with our data engine.
We tabulate the top stocks by inflows, outlfows, and holding by mainland investors.
Inflows last month amounted to USD 5.7bn which marks sixth months of inflows. Top three stocks southbound investors bought were Meituan, CNOOC, and Tencent.


Hong Kong Connect Flows Monthly (May): Meituan, CNOOC, Tencent

Equity Bottom-Up

<ul>
<li>The CARVYKTI commercialization will bring GenScript increasing revenue and cash flow. Together with the rapid growth of GCT CDMO, it is expected to see gradual improvement in GenScript’s financial performance.</li>
<li>The complex international relations, geopolitical conflicts and anti-globalization risks could weigh on bullish sentiment in the short term or cause stock prices to fluctuate wildly.</li>
<li>In the long term, GenScript’s “all-in” on GCT area enables it follow the industry trend closely. So,GenScript have the exponential growth potential in valuation, with possibility of surpassing WuXi Biologics.</li>
</ul>


The CARVYKTI commercialization will bring GenScript increasing revenue and cash flow. Together with the rapid growth of GCT CDMO, it is expected to see gradual improvement in GenScript’s financial performance.
The complex international relations, geopolitical conflicts and anti-globalization risks could weigh on bullish sentiment in the short term or cause stock prices to fluctuate wildly.
In the long term, GenScript’s “all-in” on GCT area enables it follow the industry trend closely. So,GenScript have the exponential growth potential in valuation, with possibility of surpassing WuXi Biologics.


Genscript Biotech - Commercialized CAR-T & Strong CGT CDMO Indicate Exponential Growth in Valuation

China

WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland.  We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wuxi Biologics (2269 HK)

Hong Kong Connect Flows: Kuaishou, Wuxi Biologics, HKEx

We highlight weekly southbound Hong Kong connect inflows into Kuaishou, Wuxi Biologics, and Hong Kong Exchange, and outflows from CNOOC, China...

Ke Yan, CFA, FRM

China Healthcare Weekly (Jun.10) - Medical Service Price Reform, Medical Device CXO, Lockdown Lifted

China medical system reform will increase overall service price; Medical device CXO is popular but has a long way to go; SH lockdown has lifted,...

Xinyao (Criss) Wang

Hang Seng Index Constituents 8th June 2022

I got Alibaba spectacularly wrong. The government allowed the release of new games and eased some restrictions on the tech sector.

Untying The Gordian Knot

Hong Kong Connect Flows Monthly (May): Meituan, CNOOC, Tencent

Inflows last month amounted to USD 5.7bn which marks sixth months of inflows. Top three stocks southbound investors bought were Meituan, CNOOC, and...

Ke Yan, CFA, FRM

Genscript Biotech - Commercialized CAR-T & Strong CGT CDMO Indicate Exponential Growth in Valuation

GenScript’s commercialization of CAR-T, rapid growing GCT CDMO and “all-in” on GCT industry chain indicate exponential growth potential in...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)